Introduction
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, with survival times ranging from months to decades [1, 2, 3] . Clonal genomic aberrations can be identified in approximately 80% of CLL patients by fluorescent in situ hybridization (FISH), and they constitute one of the most important predictors of disease progression and survival.
The most common recurrent chromosomal abnormalities include: 13q deletion (13q-); 11q deletion (11q-); trisomy 12 (+12); and 17p deletion (17p-), defining five prognostic categories with survival times ranging from 32 months in patients with 17p-to 133 months in patients with 13q-as the sole abnormality [4] . Recently, a new prognostic scoring system which separates CLL patients into four prognostic risk groups has been published: high-risk, harboring TP53 and/or BIRC3 abnormalities (10-year OS: 29%); intermediate-risk, harboring NOTCH1 and/or SF3B1 mutations and/or del(11q22-q23) (10-year OS: 37%); low-risk, harboring trisomy 12 or a normal genetics (10-year OS: 57%); and very low-risk, harboring del(13q) only, whose 10-year OS (69.3%) did not significantly differ from a matched general population [5] .
Trisomy 12 is the third most frequent cytogenetic aberration in CLL, occurring in up to 15-20% . It often appears as the unique cytogenetic alteration (40-70% of cases with +12), although it can be associated with other chromosomal aberration [6] .
The critical genes involved in this aberration remain unknown [7] and it has been associated with an atypical morphology or immunophenotype [8] . CLL patients with this aberration have been classically considered to have an intermediate prognosis [4] , although evidence from prospective trials suggests that overall survival is favorable despite progression-free survival may be shorter [7, 9] .
CLL patients with +12 rarely show TP53 mutations and rarely acquire these over time, finding that may partly explain the benign course after treatment [5, 10] . However, the presence of NOTCH-1 mutations can be identified in 30-40% of patients carrying +12, and it confers a worse disease outcome in this subset of patients [11, 12, 13, 14] .
Several studies demonstrated that the presence of a specific cytogenetic abnormality is not sufficient to identify homogeneous subgroups of patients. Thus, a high proportion of cells carrying 13q14-, or large deletions including RB1 gene are associated with a worse outcome [15, 16, 17, 18] . Similar results have been observed regarding 11q-, with a negative prognostic impact when 11q-involves the majority of CLL clone [19] , and regarding 17p-, with a worse clinical outcome when a higher percentage of deleted cells is present [20] . Therefore, a multicenter analysis including 289 patients diagnosed with CLL harboring +12 was carried out. We described and compared the clinical and biological characteristics of these patients, and found that a high number of +12 lymphocytes has a bad impact in the clinical outcome.
Patients and methods

Patients
An electronic database containing information from 2,561 patients diagnosed with CLL from 25 Spanish institutions was retrospectively screened. The diagnosis was based according to the World Health Organization Classification of Tumors [21] and International Workshop on CLL guidelines [22] . All (289) cases carrying +12 detected in the routine FISH analysis were selected. Clinical information recorded at diagnosis 
FISH analysis
Interphase FISH was performed on peripheral blood samples at the time of diagnosis using commercially available probes for the following regions: 11q22/ATM, 12q13, 13q14 and 17p13/TP53 (Vysis/Abbott Co, Downers Grove, IL, USA). Methods for FISH analysis are described elsewhere [23] . Dual color FISH using differently labeled control probes was performed, and signal screening was carried out on at least 200 cells with well delineated signals. Hybridization was repeated in those slides with less than 80% cells showing two control-probe signals. The sensitivity limit for the detection of +12 and deletions were >5%, and >10% interphase cells with three signals and one signal respectively.
Statistical analysis
Statistical analysis was performed using the SPSS 21.0 software package (SPSS, Chicago, IL, USA). The cut-off point for percentage of +12 was selected by dividing the variable into deciles and selecting the most efficient cut-point. The Fischer´s exact test and the Chi-squared test were used to determine the relationship between categorical variables. Quantitative variables were compared by using the Student-t test and the Mann-Whitney U test.
OS was calculated from the time of diagnosis to death or last follow-up visit. TTFT was calculated as the interval between diagnosis and the start of first line treatment. OS and TTFT were estimated by the Kaplan-Meier method and assessed by the log-rank test.
Univariate and multivariate analysis were performed using Cox regression method.
Statistical significance was defined as P < 0.05.
Results
Patient characteristics
FISH detected +12 in 355 patients (13.9%) of the 2,461 patients initially included in the study. The final analysis was limited to 289 cases, after excluding monoclonal B-cell lymphocytosis, cases that acquired +12 as clonal evolution, or with inadequate followup. Median age was 68 years old (range, 22-88 years). A hundred and seventy-eight patients were male (61.6%). At the time of diagnosis, most cases were classified as stage A (68.9%), while only 5.2% were in stage C according to Binet classification [3] .
Median white blood cell (WBC) count was 19x10 9 Figure S1B ).
We could not find any difference in TTFT or OS when +12 was accompanied by 17p-or 13q-. It is remarkable that most of the patients with 11q-(7/9) presented it in ≥ than 25% of 11q deleted nuclei.
Discussion
Cytogenetic abnormalities confer an important prognostic value in CLL [3] . However, recent studies have demonstrated that cytogenetic groups might be heterogeneous, and that the percentage of cells that display a specific abnormality could be related to the prognosis of these subgroups [15, 19, 209] . These observations have not been confirmed before in patients carrying +12. For these reasons, we performed a multicentric analysis of patients diagnosed with CLL and +12 focusing on the prognostic value that the percentage of cells with this abnormality may imply. We observed that patients with +12 constitute a heterogeneous group with intermediate prognosis, with a poor outcome in the subgroup of patients with a higher proportion of cells carrying +12.
Trisomy 12 was present in 13.5% of the patients, being the median OS of 129 months, and median TTFT of 42 months. These findings are consistent with previous publications that estimate frequency of +12 around 15-20%, with a median OS of 111 months, and a median TTFT of 32 months [4] . The other clinical characteristics of the present series, such as the median age (68 years), with a male predominance; the predominance of low lymphocyte count (83%), low β 2 microglobulin levels (71%), early Binet stages (71%), low levels of CD38 (63%), and absence of significant organomegaly, are also in accordance to previous studies [4, 7] .
The percentage of cells displaying +12 identified 2 subgroups of patients with different prognosis. Interestingly, patients with a higher proportion of +12 cells presented with higher WBC and lymphocyte count; higher levels of LDH and β 2 microglobulin; more advanced Binet stages; and splenomegaly. More patients with a high proportion of cells with +12 needed treatment or died during follow up.
Of note, the group of patients with +12 in < 60% of their cells, showed a significantly longer TTFT and OS. Moreover, in the multivariate analysis, the independent effect of this covariate remained on TTFT.
To better define prognostic features among all the group of patients with +12, several factors predicting a shorter TTFT were identified. Thus, advanced Binet clinical stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, and high LDH were associated with shorter TTFT. It is remarkable that the presence of >60% of cells with +12, advanced Binet stage, high lymphocyte count, and B symptoms remained significantly associated with a worse TTFT in the multivariate analysis. These results are similar to the published studies in the overall setting of CLL cases [4, 8, 13 ].
We also found that similar factors were associated with a shorter OS, including advanced Binet stage, lymphadenopathy, splenomegaly, high LDH, high β 2 microglobulin, and expression of CD38. However, only advance Binet stage, and high β 2 microglobulin remained independently significant in predicting OS.
As speculated with other cytogenetic abnormalities, it may be possible that the greatest number of losses in 13q 11q, or 17p deletions or a high percentage of cells with +12, translates genetic instability that makes the outcome of these patients worse. In our series we found that 60% of cells with +12 was the better cut-off with clinical significance, after trying different thresholds. However, further studies preferably in a prospective context need to be performed to validate this limit.
We could not find predictive value regarding other important prognostic factors such as IGHV mutation status, and expression of ZAP-70. Nevertheless, data were collected retrospectively, and these factors were not analyzed in the whole series of patients.
Coexistence of other cytogenetic abnormalities in addition to +12 was rare in our cohort, and it is consistent with previous publications [6, 7, 10] . Only 19% of patients presented other cytogenetic abnormalities, being 13q-the most frequent followed by 17p-and 11q-. We analyzed TTFT and OS in the different cytogenetic abnormalities, and we found a significantly shorter TTFT and OS in the group of patients with 11q-.
This covariate preserved its effect in the multivariate analysis. We failed to observe these findings in the subgroup of patients with 17p-. Moreover, only a tendency to a longer OS in patients with 13q-was observed. It is noteworthy that even though 11q-was only present in 9 patients, nearly all of them presented it in ≥ than 25% of 11q deleted nuclei, which has previously been associated with a worse outcome [8] .
However, larger studies with more patients are needed to ascertain these findings, and address the relationship between +12 and other cytogenetic abnormalities.
To summarize, our findings suggest that the percentage of cells carrying +12 influences the outcome of these patients. We demonstrated that a high proportion of cells with +12
detected by FISH is associated with a short OS and TTFT. Our results suggest the need to consider the percentage of cells with +12 as an important prognostic factor, in future prognosis scales.
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Supporting information Figure S1. Kaplan-Meier curves for: time to first therapy (TTFT) in patients with +12 and 11q-(A); and overall survival (OS) in patients with +12 and 11q-(B). 
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